Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2015, Vol. 9 Issue (1) : 112-116     DOI: 10.1007/s11684-014-0345-z
A case of primary neuroendocrine breast carcinoma that responded to neo-adjuvant chemotherapy
Xiaolong Wei1,Chunfa Chen2,3,Didi Xi2,3,Jinwen Bai2,3,Wenhe Huang3,Luoxiang Rong2,3,Mingyao Wu4,Guojun Zhang2,3,*()
1. Department of Pathology, Cancer Hospital of Shantou University Medical College, Shantou 515031, China
2. Cancer Research Center, Shantou University Medical College, Shantou 515031, China
3. The Breast Center, Cancer Hospital of Shantou University Medical College, Shantou 515031, China
4. Department of Pathology, Shantou University Medical College, Shantou 515031, China
Download: PDF(795 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Primary neuroendocrine breast carcinoma (NEBC) is a very rare type of breast cancer. Two characteristic biomarkers, namely, CgA and Syn, should be immunohistochemically detected to diagnose NEBC. In this study, a 43-year-old woman with a large mass of 8.3 cm × 2.9 cm in her right breast was reported. The patient was pathologically diagnosed with NEBC after specific markers, including CgA and Syn, as well as few differential markers, such as CK7, ER, PR, C-erbB-2, NSE, and E-cadherin, were immunohistochemically detected. The patient showed a remarkable response to four cycles of neo-adjuvant chemotherapy (partial response based on RECIST criteria) and sequentially underwent modified radical mastectomy. Moreover, the diagnosis and treatment of NEBC based on this case and available related literature were discussed.

Keywords neuroendocrine carcinoma      neo-adjuvant therapy      breast     
Corresponding Authors: Guojun Zhang   
Online First Date: 11 August 2014    Issue Date: 02 March 2015
URL:     OR
Fig.1  Mammographic finding of the right breast. (A) Mammographic image of primary NEBC before neo-adjuvant chemotherapy. A lobulated lump with a size of 8 cm×3 cm and high-density echo; enlarged lymph nodes with a diameter of 1.8 cm are also shown. (B) Mammographic image after four cycles of neo-adjuvant chemotherapy. The tumor becomes smaller with a size of 2 cm×1.5 cm; lymph nodes also become smaller.
Fig.2  Representative fields of primary NEBC. A and B show different histological morphologies of the NEBC in different regions. (A) Cells are distributed diffusely; fibrovascular intervals and cell gaps are not well defined. The cytoplasm of the cells was slightly eosinophilic and partly mucoidal. (B) Cells are distributed in a solid and sheeted manner with fibrovascular intervals. Magnification: 400×.
Fig.3  Immunohistochemical phenotype of NEBC. (A) Partially positive expression for CK7; (B) negative expression for CD56; (C) positive expression for NSE; (D) positive expression for Syn; (E) positive expression for CgA. Magnification: 400×.
1 Feyrter <?Pub Caret1?> F, Hartmann G. On the carcinoid growth form of the carcinoma mammae, especially the carcinoma solidum (gelatinosum) mammae. Frankf Z Pathol 1963; 73: 24–39(in German)
pmid: 14097474
2 Fisher ER, Palekar AS. Solid and mucinous varieties of so-called mammary carcinoid tumors. Am J Clin Pathol 1979; 72(6): 909–916
pmid: 229725
3 Azzopardi JG, Muretto P, Goddeeris P, Eusebi V, Lauweryns JM. ‘Carcinoid’ tumours of the breast: the morphological spectrum of argyrophil carcinomas. Histopathology 1982; 6(5): 549–569
doi: 10.1111/j.1365-2559.1982.tb02750.x pmid: 6183185
4 Papotti M, Macrì L, Finzi G, Capella C, Eusebi V, Bussolati G. Neuroendocrine differentiation in carcinomas of the breast: a study of 51 cases. Semin Diagn Pathol 1989; 6(2): 174–188
pmid: 2503862
5 Zadro Z, Fuduri? J, Frketi? I, Stifter S, Bujas T, Zadro AS, Veir Z, Doko I. Neuroendocrine small cell carcinoma of the breast—a case report. Coll Antropol 2012; 36(3): 1053–1055
pmid: 23213972
6 B?cker W. WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics. Verh Dtsch Ges Pathol 2002; 86: 116–119 (in German)
pmid: 12647359
7 Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45(2): 228–247
doi: 10.1016/j.ejca.2008.10.026 pmid: 19097774
8 Fujimoto Y, Yagyu R, Murase K, Kawajiri H, Ohtani H, Arimoto Y, Yamamura T, Inoue T, Moritani S. A case of solid neuroendocrine carcinoma of the breast in a 40-year-old woman. Breast Cancer 2007; 14(2): 250–253
doi: 10.2325/jbcs.889 pmid: 17485914
9 Adams RF, Parulekar V, Hughes C, Kadour MJ, Talbot D. Radiologic characteristics and management of screen-detected metastatic carcinoid tumor of the breast: a case report. Clin Breast Cancer 2009; 9(3): 189–192
doi: 10.3816/CBC.2009.n.032 pmid: 19661045
10 Sapino A, Righi L, Cassoni P, Papotti M, Pietribiasi F, Bussolati G. Expression of the neuroendocrine phenotype in carcinomas of the breast. Semin Diagn Pathol 2000; 17(2): 127–137
pmid: 10839613
11 Thomas P, Battifora H, Manderino GL, Patrick J. A monoclonal antibody against neuron-specific enolase. Immunohistochemical comparison with a polyclonal antiserum. Am J Clin Pathol 1987; 88(2): 146–152
pmid: 3618548
12 Sapino A, Bussolati G. Is detection of endocrine cells in breast adenocarcinoma of diagnostic and clinical significance? Histopathology 2002; 40(3): 211–214
doi: 10.1046/j.1365-2559.2002.01327.x pmid: 11895485
13 Maluf HM, Koerner FC. Carcinomas of the breast with endocrine differentiation: a review. Virchows Arch 1994; 425(5): 449–457
doi: 10.1007/BF00197547 pmid: 7850068
14 Sanguinetti A, Santoprete S, Lucchini R, Triola R, Loreti F, Avenia N. A rare breast tumor: solid neuroendocrine carcinoma. Ann Ital Chir 2013; 84(1): 81–85
pmid: 22672972
[1] Lan Wang,Jueheng Wu,Jie Yuan,Xun Zhu,Hongmei Wu,Mengfeng Li. Midline2 is overexpressed and a prognostic indicator in human breast cancer and promotes breast cancer cell proliferation in vitro and in vivo[J]. Front. Med., 2016, 10(1): 41-51.
[2] Aixiu Qiao,Feng Gu,Xiaojing Guo,Xinmin Zhang,Li Fu. Breast cancer-associated fibroblasts: their roles in tumor initiation, progression and clinical applications[J]. Front. Med., 2016, 10(1): 33-40.
[3] Renling Pei, Ye Xu, Yan Wei, Tao Ouyang, Jinfeng Li, Tianfeng Wang, Zhaoqing Fan, Tie Fan, Benyao Lin, Yuntao Xie. Association of SIPA1 545 C>T polymorphism with survival in Chinese women with metastatic breast cancer[J]. Front Med, 2013, 7(1): 138-142.
[4] Suchinda Malaivijitnond. Medical applications of phytoestrogens from the Thai herb Pueraria mirifica[J]. Front Med, 2012, 6(1): 8-21.
[5] Ling XU. How to judge the association of postmenopausal hormone therapy and the risk of breast cancer[J]. Front Med Chin, 2010, 4(3): 290-293.
[6] Qiong DAI MD, Bei LIU MD, Yukai DU MM, . Meta-analysis of the risk factors of breast cancer concerning reproductive factors and oral contraceptive use[J]. Front. Med., 2009, 3(4): 452-458.
[7] Haiping SONG MD, Lan SHI MD, Chunping LIU MD, Tao HUANG MD, . Expression of PC-cell-derived growth factor in breast cancer[J]. Front. Med., 2009, 3(4): 426-430.
[8] Lihui WANG, Lianhong LI, Shen LV, Shujun FAN, Li ZHAN, Bo WANG, Zhong ZHANG. Lymphatic metastasis is related to the epithelial-mesenchymal transition and expressions of VEGF, MMP-9, and COX-2 in breast cancer[J]. Front Med Chin, 2009, 3(2): 164-170.
[9] YANG Rong, ZHANG Bin, YANG Shaoping, ZHANG Dan, DU Yukai. Soy food consumption in relation to breast cancer modified by menopause status[J]. Front. Med., 2008, 2(4): 348-351.
[10] LI Zhi, HE Yanli, ZHANG Jiahua, ZHANG Jinghui, HUANG Tao. Determination of telomerase activity in stem cells and non-stem cells of breast cancer[J]. Front. Med., 2007, 1(3): 294-298.
Full text